AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01040247 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Embryo Transfer
Description: In the study group embryo transfer will be performed on the day of oocyte aspiration and fertilization while in the control group it will be done 2 or 3 days later as is common practice.
Study NCT04459728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 2: Mindfulness
Description: Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
Study NCT04459728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 3 - Sleep Hygiene
Description: Daily wellness element focusing on sleep hygiene; adherence documented online daily
Study NCT04459728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 4 - Social Connectedness
Description: Daily wellness element focusing on social connectedness; adherence documented online daily
Study NCT04459728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 5 - Nutrition
Description: Daily wellness element focusing on nutrition; adherence documented online daily
Study NCT04189484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab 21 mg administered SC
Study NCT04189484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab 35 mg administered SC
Study NCT04189484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab 70 mg administered SC
Study NCT04189484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab 140 mg administered SC
Study NCT04189484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab 15 mg administered SC
Study NCT04189484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab 25 mg administered SC
Study NCT04189484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab 50 mg administered SC
Study NCT04189484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Alirocumab 100 mg administered SC
Study NCT04189484 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered SC
Study NCT00642044 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneal Collagen Crosslinking
Description: UV light and Riboflavin eyedrops every 5 minutes for 30 minutes.
Study NCT03454035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulixertinib
Description: Ulixertinib 300mg, orally, twice a day concomitantly with palbociclib
Study NCT03454035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Drug: Palbociclib 125mg, orally, once a day concomitantly with ulixertinib
Study NCT00557440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate/salmeterol
Description: Fluticasone propionate/salmeterol 250/50 μg twice daily delivered via MDDPI.
Study NCT00557440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol maleate / mometasone furoate
Description: Indacaterol maleate / mometasone furoate 500/400 μg once daily delivered via the TWISTHALER device.
Study NCT00557440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to indacaterol/mometasone
Description: Placebo to indacaterol maleate/mometasone furoate delivered via the TWISTHALER device.
Study NCT00557440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to fluticasone propionate/salmeterol
Description: Placebo to fluticasone propionate / salmeterol delivered via MDDPI.
Study NCT01662206 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: 2 capsules daily containing Lactobacillus gasseri, Bifidobacterium bifidum and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration)
Study NCT00603980 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled alprazolam 1 mg
Description: Inhaled Staccato alprazolam 1 mg + oral placebo
Study NCT00603980 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inhaled alprazolam 2 mg
Description: Inhaled Staccato alprazolam 2 mg + oral placebo
Study NCT04459728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 6 - Wellness Exercises
Description: Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
Study NCT04459728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness Element 7 - Motivational Messages
Description: Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
Study NCT04590131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent, supplemented by fasciotomy in Hunter's canal.
Description: Under local anesthesia, a standard endovascular approach is performed. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Immediately after the stenting procedure, under local anesthesia, access to the distal part of the SFA at the outlet of Hunter's canal and 1 portion of the popliteal artery is performed. The lamina vastoadductoria is dissected. The wound is sutured in layers. An aseptic bandage is applied. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
Study NCT04590131 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: recanalization of the femoral-popliteal arterial segment above the knee with angioplasty and stenting with a biomimetic interwoven nitinol stent.
Description: Under local anesthesia, a standard endovascular approach is performed and the affected arterial segment is visualized. Transluminal or subintimal recanalization of the occluded arterial segment is performed with a hydrophilic guidewire. Next, balloon angioplasty of the recanalized segment is performed. After control angiography, a biomimetic interwoven nitinol stent is placed throughout the lesion. Drug therapy includes pre-procedure clopidogrel (160-300 mg/day), starting at least one day before, and intra-procedure heparin (100 U / kg body weight intravenously). After the procedure, all patients have prescribed double antiplatelet therapy (aspirin+clopidogrel (75 mg per day) within 6 months and then aspirin 75 mg for a long time.
Study NCT00675948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Containing delta-9-tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml; both as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours.
Study NCT00675948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW-2000-02
Description: Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
Study NCT05043909 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VR-based training
Description: Students simulate the different physical and oral conditions of the elderly through virtual situations and provide suitable oral care methods. The whole training session took approximately two hours for each student; First, students were first given a short introduction to the VR system's use (10 minutes). Second, they were able to carry out oral care for the elderly while wearing VR goggles and using hand-controllers with the teaching and audio guides during the process (90 minutes), and an evaluation was taken after the intervention (20 minutes).
Study NCT03342963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASC-01
Description: Aripiprazole 3 mg/sertraline 100 mg combination drug
Study NCT03342963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole and sertraline
Description: Aripiprazole 3 mg and sertraline 100 mg
Study NCT01667484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adderall XR 5mg
Study NCT01667484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adderall XR 10 mg
Study NCT01667484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01760720 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MMT CARE
Study NCT03466567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: A single dose of 3 mg semaglutide tablet alone will be administered orally. Trial product administration will take place in the morning after overnight fasting for at least 6 hours.
Study NCT03466567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: A dose of 500 mg probenecid (2 tablets of 250 mg) will be administered orally twice daily for 3½ days (7 trial product administrations in total). On the 4th day, the last probenecid administration will take place 2 hours prior to administration of a single dose of 3 mg oral semaglutide tablet. The last trial product administrations will take place in the morning after overnight fasting for at least 6 hours.
Study NCT03466567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclosporin
Description: A single dose of 600 mg ciclosporin (6 capsules of 100 mg) will be administered orally 1 hour prior to administration of a single dose of 3 mg oral semaglutide tablet. Trial product administration will take place in the morning after overnight fasting for at least 6 hours.
Study NCT04558944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporal Shock Wave Therapy
Description: Acoustic high amplitude waves with Energy Flux Density of 0.15mJ/mm 2 and 512 pulses per session. A total of two sessions per week during a 4-week period.
Study NCT01476956 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: RA patients on standard DMARD therapy
Study NCT00816296 — intervention group
Intervention type: OTHER
Intervention: Blood Draw
Description: 2 tablespoons of blood will be drawn from participants at study entry, 3 months after study entry, and 6 months after study entry.
Study NCT00816296 — intervention group
Intervention type: OTHER
Intervention: Stool collection
Description: Stool will be collected from participants 3 times during the study -- at study entry, 3 months from study entry, and 6 months after study entry.
Study NCT00816296 — intervention group
Intervention type: OTHER
Intervention: BodPod Measurement
Description: Body composition will be measured using a BodPod at study entry, 3 months after study entry, and 6 months after study entry.
Study NCT00816296 — intervention group
Intervention type: OTHER
Intervention: Liver Ultrasound
Description: A liver ultrasound will be performed at study entry and 6 months after study entry.
Study NCT03597880 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: obese patients
Description: underwent bariatric surgery
Study NCT03922126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer counseling
Description: Information, motivation, and behavioral skills for HIV/STI testing and pre-exposure prophylaxis uptake
Study NCT03922126 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peer counseling
Description: Information, motivation, and behavioral skills for HIV/STI testing and pre-exposure prophylaxis uptake
Study NCT03922126 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HIV/STI self-testing kits
Description: Kits to self-test for HIV/STIs
Study NCT03155971 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Coated Balloon
Description: SeQuent ® Please; B.Braun, Melsungen, Germany
Study NCT01236482 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin versus oxytocin-ergometrine
Description: Group 1: Oxytocin 0.1 I.U./kg/hr (plain) Group 2: Oxytocin 0.1 I.U./kg/hr with ergometrine 2 mcg/kg/hr co-administered Infusion rates determined to achieve equipotential doses based on an earlier PKPD study
Study NCT01236482 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin versus oxytocin-ergometrine
Description: Group 1: Oxytocin 0.1 I.U./kg/hr (plain) Group 2: Oxytocin 0.1 I.U./kg/hr with ergometrine 2 mcg/kg/hr co-administered Infusion rates determined to achieve equipotential doses based on an earlier PKPD study
Study NCT02459301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPH2201
Study NCT01655771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211 Dose 1
Study NCT01655771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-1211 Dose 2
Study NCT01662206 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules daily containing 348.25 mg of potato starch
Study NCT03401866 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: DSC-MRI
Description: The multiple dose protocol with sequential DSC-MRI scans enables comparison of BTIP compliant and double-dose injections schemes.
Study NCT01115504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Thiamine
Description: 300 mg daily for 30 days
Study NCT01115504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: 300 mg daily for 30 days
Study NCT01006148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenix Plus
Description: It is a demineralized bone matrix obtained using cortical or cancellous allograft bone that is treated to remove surface lipids and then dehydrated with ethanol and ethyl esther. It is further processed leaving behind proteins, bone growth factors, and collagen. It is combined with lecithin a which is resistant to breakdown by body fluids. It contains Pro Osteon Implant 500R a naturally derived material made from a non-decorative form of coral, which is subject to a patented thermal process, which converts the coral to hydroxyapatite.
Study NCT03527667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Treatment arm participants will receive financial incentives ($20 per week) contingent on biochemically verified smoking abstinence submitted once daily for the time period allocated.
Study NCT01164826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabumetone
Description: Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
Study NCT01164826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Relafen
Description: Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
Study NCT00659022 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: immediate surgery (resection of primary colorectal tumor)
Description: no neo-adjuvant treatment, immediate surgery
Study NCT00562835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Drug: Methylprednisolone Day 0 Loading dose 1 mg/kg IV bolus (30 min) followed by continuous infusion; Days 0 to 14\*† ‡ 1 mg/kg/day mixed in 240cc Normal saline (NS) and infused at 10 cc/hr; Days 15 to 21\*‡ 0.5 mg/kg/day mixed in 240cc NS and infused at 10 cc/hr; Days 22 to 25\*‡ 0.25 mg/kg/day; Days 26 to 28\*‡ 0.125 mg/kg/day~\*Five days after the patient is able to ingest medications, methylprednisolone is given per os in one single daily equivalent dose.~†If between days 1 to 14 the patient is extubated, he is advanced to day 15 of drug therapy and tapered according to schedule.~‡ When leaving ICU, if the patient is still not tolerating p.o. intake for at least five days, he should receive the specified dosage as IV push every 6 hours until tolerating oral ingestion
Study NCT00562835 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline intravenously and vitamin B1 per os
Description: Patients in this group will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 25 cc \[prednisolone + diluting fluid\], then the patient will receive 25 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm. Five days after the patient is able to ingest medications, placebo is administered per os in one single daily equivalent dose. The placebo will be a Vitamin B1 (thiamine) 50-mg tablet. We will now designate each placebo tab as a 16-mg equivalent to each tablet of active drug. These tablets are scored and half tabs can be given if needed. Therefore if a patient is receiving 40 mg of study drug: 40/16 = 2.5 tabs x 50 mg = 125 mg actual dose of thiamine.
Study NCT02577549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet & Exercise
Description: Participants will attend exercise and diet classes.
Study NCT02577549 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Participants will attend healthy living classes and receive health newsletters and phone calls/emails/texts.
Study NCT00762229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe 10 mg
Description: Ezetimibe 10 mg daily for 4 weeks
Study NCT00762229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 5 mg
Description: Ezetimibe 5 mg daily for 4 weeks, formulated as a 10 mg tablet split in half
Study NCT02760797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emactuzumab
Description: Emactuzumab will be administered IV every 3 weeks (every cycle) during Part I and every 3 or 6 weeks (every cycle or every other cycle) during Part II.
Study NCT02760797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7009789
Description: RO7009789 will be administered IV every 3 weeks (every cycle).
Study NCT03074955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: leg wrapping with tension
Description: 1. Apply elastic bandages with tension to both legs before injecting propofol.~2. After 3 minutes, remove elastic bandages.
Study NCT03074955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trendelenburg position
Description: 1. Apply Trendelenburg position positon of 10 degree after injectin propofol~2. After 3 minutes, change to supine position
Study NCT03074955 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: leg wrapping without tension
Description: 1. Apply elastic bandages without tension to both legs before injecting propofol.~2. After 3 minutes, remove elastic bandages
Study NCT03074955 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: supine position
Description: 1.maintain supine position
Study NCT03074955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supine position
Description: 1.maintain supine position
Study NCT03849248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal scent cloth
Description: The babies assigned to the intervention group will have a cloth with their mother's scent on it placed under their heads.
Study NCT04337801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure
Description: The acupressure for symptom management is performed by pressing and scrubbing-like manipulations at certain points on the acupuncture meridians.
Study NCT04337801 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo intervention involves touching to the Pericardium 6 and Large Intestine 4 points without pressing.
Study NCT04289662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-924 LD
Description: Pitavastatin 2 mg / Ezetimibe 10 mg tables
Study NCT04289662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-924 HD
Description: Pitavastatin 4 mg / Ezetimibe 10 mg tables
Study NCT02435446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cone-beam computed tomography
Description: Cone-beam computed tomography
Study NCT01953107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Ferrous Fumarate
Study NCT01953107 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03722823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tucatinib
Description: 300mg oral single dose
Study NCT03722823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: 300mg oral single dose
Study NCT01665651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yougui granules
Description: Yougui granules is traditional Chinese patent medicine used to treatment patients with kidney Yang deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
Study NCT01665651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zuogui granules
Description: Zuogui granules is traditional Chinese patent medicine used to treatment patients with kidney Yin deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
Study NCT01665651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Yougui granules placebo
Description: Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.